Liraglutide for Weight Loss
Research, mechanism, dosing, and effectiveness of Liraglutide for weight loss.
Quick Answer
Liraglutide (Saxenda) is FDA-approved for weight loss. Produces 5-10% body weight reduction in clinical trials.
Evidence Level
FDA Approved
Typical Dose
3 mg daily subcutaneous
Results Timeline
Weight loss over 3-6 months
FDA Status
FDA Approved
How Liraglutide Works for Weight Loss
GLP-1 agonist reduces appetite and slows gastric emptying.
About Weight Loss
Reduction of body fat and overall body weight through appetite control and metabolic enhancement.
Research Evidence
SCALE trials showed 5-10% weight loss. LEADER trial demonstrated cardiovascular benefits in diabetics. Extensive long-term safety data available. First GLP-1 approved specifically for weight management (Saxenda).
Dosing for Weight Loss
Recommended Dose
3 mg daily subcutaneous
Frequency
Once daily
Administration
Subcutaneous injection daily
Duration
Long-term / chronic use
Note: FDA-approved GLP-1. Daily injection. Victoza (diabetes) or Saxenda (weight loss). Titrate up weekly.
What to Expect
Initial adjustment period. Some users may notice subtle changes.
Early benefits often become noticeable. Continue consistent use.
Most users report meaningful improvements by this point.
Full effects typically realized. Reassess and adjust as needed.
Possible Side Effects
Not everyone experiences these. Individual responses vary.
- •Nausea (common)
- •Vomiting
- •Diarrhea
- •Constipation
- •Headache
- •Hypoglycemia (with insulin/sulfonylureas)
Frequently Asked Questions
Does Liraglutide help with weight loss?
Liraglutide (Saxenda) is FDA-approved for weight loss. Produces 5-10% body weight reduction in clinical trials.
How does Liraglutide work for weight loss?
GLP-1 agonist reduces appetite and slows gastric emptying....
What dose of Liraglutide should I use for weight loss?
3 mg daily subcutaneous
How long until I see results?
Weight loss over 3-6 months
Other Peptides for Weight Loss
These peptides are also researched for weight loss.
Semaglutide
FDAA GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.
Cagrilintide
Clinical TrialsA long-acting amylin analog developed by Novo Nordisk for obesity treatment. Works through a different mechanism than GLP-1 agonists, targeting amylin receptors in the brain to reduce appetite and slow gastric emptying. Shows enhanced weight loss when combined with semaglutide (CagriSema).
Tirzepatide
FDAA dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.
Dulaglutide
FDAAn FDA-approved weekly GLP-1 receptor agonist for type 2 diabetes. Fused to an Fc antibody fragment for extended duration of action.
Educational Information Only
This information about Liraglutide for weight loss is for educational purposes only. Always consult with qualified healthcare providers before using any peptide. Individual results may vary.